C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?Zacks Investment Research • 07/17/24
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024GlobeNewsWire • 07/16/24
C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation DayGlobeNewsWire • 07/08/24
C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/08/24
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 04/29/24
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024GlobeNewsWire • 04/08/24
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024GlobeNewsWire • 03/05/24
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic ProteinsGlobeNewsWire • 03/04/24
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 02/22/24
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 02/22/24
C4 Therapeutics, Inc. (CCCC) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacks Investment Research • 02/15/24
C4 Therapeutics, Inc. (CCCC)'s Technical Outlook is Bright After Key Golden CrossZacks Investment Research • 01/10/24
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation MedicinesGlobeNewsWire • 01/09/24
C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta PharmaceuticalsGlobeNewsWire • 01/04/24
C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/24
Wall Street Analysts See a 197.7% Upside in C4 Therapeutics, Inc. (CCCC): Can the Stock Really Move This High?Zacks Investment Research • 01/01/24
Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 222.95%: Read This Before Placing a BetZacks Investment Research • 12/15/23